Alector Inc. (ALEC)
NASDAQ: ALECHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 1.89 -1.54%
ALEC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $214.38M
- EPS (TTM)
- -$1.09
- Dividend yield
- None
- 52-week range
- 1.09 – 3.40
- Day range
- 1.73 – 1.92
- Volume / Avg
- 3.95M / 2.75M
- Beta
- —
- Shares outstanding
- 111.66M
- Next earnings
- Nov 5, 2026
52-week range
ALEC stock today
On Oct 7, ALEC ended the session at $1.92, adding $0.11 (6.08%), versus the S&P 500's 0.22% decline. Shares are 43.5% below their 52-week high of $3.40, set on Oct 16, 2025 and 76.1% above the 52-week low of $1.09, in the middle of the past year's range. ALEC is up 23.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 37.5%.
Alector has posted a net loss over the last twelve months (EPS of -$1.09), so its P/E ratio is not meaningful. Alector's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Alector
Company profileAlector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Arnon Rosenthal Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 103
- IPO year
- 2019
- Website
- alector.com
Analyst forecast
ForecastConsensus (7 analysts)
hold
Avg. price target
$3.30+71.88%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.25
ALEC news
All ALEC newsAlector peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVVDInvivyd Inc. | 0.7286 | -9.65% | $214.76M | vs ALEC |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.71 | -0.73% | $218.35M | vs ALEC |
| CGENCompugen Ltd. | 2.15 | -3.15% | $203.66M | vs ALEC |
| IPSCCentury Therapeutics Inc. | 1.28 | -3.03% | $231.78M | vs ALEC |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs ALEC |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs ALEC |
| CMPXCompass Therapeutics Inc. | 1.02 | +2.19% | $183.69M | vs ALEC |
| DTILPrecision BioSciences Inc. | 6.25 | +0.81% | $172.51M | vs ALEC |
Indexes, lists and sector
Alector stock FAQ
What is Alector's stock price today?
ALEC last traded at $1.92 as of Oct 7, 4:00 PM EDT, up 6.08% on the day. Prices are delayed at least 15 minutes.
When is Alector's next earnings date?
Alector is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.25.
Who is Alector's CEO?
Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector Inc., which has about 103 employees.
What is the ALEC 52-week high?
The 52-week high for ALEC is $3.40 and the 52-week low is $1.09. The stock is currently 43.5% below its high.